Search Results

You are looking at 231 - 240 of 2,881 items for :

  • Refine by Access: All x
Clear All
Full access

HSR24-153: Real-World Clinical Outcomes of First-Line Therapies and Treatment Regimens for BRAF-Mutant Advanced/Metastatic Melanoma: Retrospective Observational Study

Ruixuan Jiang, Geoffrey Johnson, Emilie Scherrer, John Kang, Kathleen M. Aguilar, Rohini Singh, and Eric D. Whitman

Background: The aim of this real-world study was to compare clinical outcomes for patients with BRAF-mutant advanced/metastatic melanoma who received first-line (1L) anti-PD1 monotherapy or 1L BRAF/MEK inhibitor therapy, accounting for second

Full access

Mobile Technology-Based (mLearning) Intervention to Enhance Breast Cancer Clinicians' Communication About Sexual Health: A Pilot Trial

Jennifer Barsky Reese, Lauren A. Zimmaro, Sharon L. Bober, Kristen Sorice, Elizabeth Handorf, Elaine Wittenberg, Areej El-Jawahri, Mary Catherine Beach, Antonio C. Wolff, Mary B. Daly, Brynna Izquierdo, and Stephen J. Lepore

communication skills development, 22 – 24 and social cognitive theory, which emphasizes individuals’ beliefs (ie, self-efficacy and outcome expectancies) as critical processes underlying successful behavioral interventions. 22 , 25 – 28 We adapted the

Full access

Additional Abstracts from the NCCN 21st Annual Conference: Advancing the Standard of Cancer Care™

interventions to minimize distress and improve patient quality of life. AB2016-29. Treatment Outcomes in Patients With Metastatic Neuroendocrine Tumors: Retrospective Analysis of a Community Oncology Database Maxine D. Fisher, PhD a ; Sonia Pulgar, MPH b

Full access

CGE21-031: Genomic Biomarker Testing, Treatments, and Survival Outcomes Among Patients With Advanced or Metastatic NSCLC in the US: A Retrospective Cohort Study

Yajun Zhu, Yimei Han, Naleen Raj Bhandari, and Lisa Hess

Objectives: This study identified factors associated with genomic biomarker testing (“tested” vs “not tested”) and examined the association of the receipt of treatment that is guided by genomic biomarker testing results with survival outcomes among

Full access

HSR21-067: What Patient-Reported Outcomes Are Being Used in Non-small Cell Lung Cancer? A Targeted Literature Review of Randomized Clinical Trials and Regulatory Labeling

Kajal Patel, Soham Shukla, Jennifer Hanlon, Kelly Bell, Laurie Eliason, and Cosmina Hogea

-reported outcome (PRO) data, an important resource in the field of oncology, has the potential to offer direct insight into the patient’s treatment experience, beyond efficacy and safety measures. Methods: A targeted literature search for PROs was performed using

Full access

HSR20-105: The Impact of Gastric Cancer Clinical Pathways Based on National Comprehensive Cancer Network Guidelines on Treatment Heterogeneity and Clinical Outcomes in the US Oncology Network

Scott Paulson, Curtis Waycaster, Bismark Baidoo, Astra M. Liepa, Anindya Chatterjee, and Lisa M. Hess

Background: It is generally assumed that adherence to clinical practice guidelines can reduce treatment variability and improve patient outcomes. Gastric cancer clinical treatment pathways were implemented in the US Oncology Network (USON) in

Full access

HSR20-108: Treatment Patterns and Outcomes in US Adults with Metastatic Non-Small Cell Lung Cancer: A Retrospective Cohort Study of First-Line Treatments

Ashley Tabah, David Huggar, Ronda Copher, Marc Tian, and Ali McBride

real-world treatment patterns and outcomes in metastatic NSCLC patients treated with a first line (1L) therapy. Methods: A retrospective cohort analysis of IBM MarketScan@ Commercial and Medicare Supplemental Claims Databases was conducted. The

Full access

BPI24-021: Impact of Social Determinants (SDOH) on Surgery and Patient Outcomes in Early-Stage Non–Small Cell Lung Cancer (eNSCLC)

Atharv Sharma, Manu Prasad, Tianyuan Hu, Arunav Saikia, Prabhakar Gaur, Venkata Sai Sumanth Pulluri, and Stuti Jha

Background: Disparities in eNSCLC treatment related to SDOH factors are a significant concern. This study used real-world data to assess how SDOH impacts patient outcomes and the time taken to receive surgery. Method: The study included 18

Full access

HSR24-123: High Dose Rate Interstitial Brachytherapy for Squamous Cell Carcinoma of the Vagina: Methods and Outcomes at a Single Institution

Jonathan C. Bastick III, Andrés Portocarrero Bonifaz, Bryce Forry, Maxwell Kassel, Salman Syed, Grant W. McKenzie, Keith T. Sowards, Jeremy T. Gaskins, and Scott R. Silva

Background: Due to the rarity of the disease, limited data exists regarding treatment for squamous cell carcinoma (SCC) of the vagina. Our goal was to evaluate the toxicity and outcomes of vaginal cancer patients treated with external beam

Full access

CLO21-022: Efficacy and Safety Outcomes With Therapies for Stage I-III Merkel Cell Carcinoma (MCC): A Systematic Literature Review

David Miller, Roberto Palencia, Ting Yu, Amrita Sandhu, Sarah Webb, Tom Blaikie, and Murtuza Bharmal

studies with efficacy and safety outcomes with relevant interventions in patients with stage I-III MCC. The review included monotherapies or combinations of pharmacological treatments, radiotherapy (RT), chemotherapy (CT), and surgery (SUR). Adjuvant (adj